8-K
Veracyte Announces Third Quarter 2026 Financial Results and $100 Million Share Repurchase Program
8-K
Veracyte Acquires Convergent Genomics to Expand Urology Diagnostics Portfolio
8-K
Veracyte Reports Strong Second Quarter 2026 Financial Results and Raises Full-Year Guidance
8-K
Veracyte, Inc. Announces Results of 2026 Annual Meeting of Stockholders
8-K
Veracyte Reports Strong First Quarter 2026 Financial Results and Raises Full-Year Guidance
8-K
Veracyte, Inc. Appoints Dr. Kevin Haas as Chief Development and Technology Officer
